14-day Premium Trial Subscription Sign Up For FreeGet Free
Nasdaq - Total Crash or Bounce-Up? Click To Watch.

$0.0144 (0.70%)

Volume: 193.192k

Closed: Sep 29, 2022

Hollow Logo Score: 0.270

Genocea Biosciences Stock Forecast

$0.0144 (0.70%)

Volume: 193.192k

Closed: Sep 29, 2022

Score Hollow Logo 0.270

Genocea Biosciences Company Profile

100 Acorn Park Drive, 5th Floor

Cambridge MA 02140

617 876 8191

www.genocea.com

Industry: Biotechnology

Sector: Healthcare

Genocea Biosciences

Description

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Hot Stocks To Watch:

IMPROVE YOUR TRADING GAME WITH A GOLDEN STAR

From 26 746 stocks, only a few dozen will trigger such a signal!

About Genocea Biosciences

Genocea Biosciences Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of so... GNCA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT